Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Free Report) gapped down prior to trading on Monday. The stock had previously closed at $3.92, but opened at $3.38. Aclaris Therapeutics shares last traded at $3.4640, with a volume of 2,287,360 shares.
Wall Street Analysts Forecast Growth
Several brokerages have recently commented on ACRS. Wedbush dropped their price target on shares of Aclaris Therapeutics from $10.00 to $8.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 28th. Craig Hallum set a $9.00 price target on Aclaris Therapeutics in a report on Wednesday, October 28th. Canaccord Genuity Group increased their target price on shares of Aclaris Therapeutics from $10.00 to $13.00 and gave the company a “buy” rating in a research note on Friday, October 30th. HC Wainwright reiterated a “buy” rating and set a $16.00 price target on shares of Aclaris Therapeutics in a research note on Wednesday, October 28th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Aclaris Therapeutics in a report on Monday, September 21st. Three research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and an average price target of $11.33.
Get Our Latest Analysis on Aclaris Therapeutics
Aclaris Therapeutics Trading Down 9.1%
Aclaris Therapeutics (NASDAQ:ACRS – Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The biotechnology company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.04. The firm had revenue of $1.48 million during the quarter, compared to analysts’ expectations of $1.27 million. Aclaris Therapeutics had a negative return on equity of 59.19% and a negative net margin of 1,244.09%. On average, equities analysts predict that Aclaris Therapeutics, Inc. will post -0.56 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of the stock. BlackRock Inc. acquired a new stake in shares of Aclaris Therapeutics during the 2nd quarter valued at $53,096,000. Rock Springs Capital Management LP lifted its holdings in shares of Aclaris Therapeutics by 0.4% during the first quarter. Rock Springs Capital Management LP now owns 4,472,650 shares of the biotechnology company’s stock worth $16,772,000 after purchasing an additional 18,909 shares during the period. Braidwell LP lifted its holdings in Aclaris Therapeutics by 26.1% during the 2nd quarter. Braidwell LP now owns 2,142,348 shares of the biotechnology company’s stock worth $11,333,000 after buying an additional 443,232 shares during the period. Kalehua Capital Management LLC acquired a new position in shares of Aclaris Therapeutics in the first quarter worth approximately $6,871,000. Finally, Palo Alto Investors LP bought a new stake in shares of Aclaris Therapeutics in the 2nd quarter valued at $8,535,045. Institutional investors own 98.34% of the company’s stock.
Aclaris Therapeutics Company Profile
Aclaris Therapeutics is a biopharmaceutical company focused on discovering and developing treatments for immuno-inflammatory diseases. Its research programs include small-molecule therapies designed to target pathways involved in inflammation and immune responses. The company’s development portfolio has included candidates for dermatologic and other inflammatory conditions. Aclaris previously developed ESKATA, a topical treatment for raised seborrheic keratoses that received U.S. regulatory approval in 2017.
See Also
- Five stocks we like better than Aclaris Therapeutics
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
- Embraer’s Record Backlog Looks Promising, But Can It Keep Its Margins Climbing?
- Could Big Buybacks Be the Next Catalyst for These 3 AI Stocks?
- 3 AI Hardware Leaders Are Raising Dividends, But Which Offers More Income?
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
